Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Eric Amela"'
Autor:
Halima Abahssain, Amine Souadka, Rania Alem, Matteo Santoni, Nicola Battelli, Eric Amela, Antoine Lemaire, Joseph Rodriguez, Hassan Errihani
Publikováno v:
Current Oncology, Vol 31, Iss 7, Pp 3771-3782 (2024)
Background: Triple-negative breast cancer (TNBC) remains a clinically challenging subtype due to its aggressive nature and limited treatment options post-neoadjuvant failure. Historically, capecitabine has been the cornerstone of adjuvant therapy for
Externí odkaz:
https://doaj.org/article/b28ed103470145c18191bbfa4c32f55d
Autor:
Diane Pannier, Antoine Adenis, Emilie Bogart, Eric Dansin, Stéphanie Clisant-Delaine, Emilie Decoupigny, Anne Lesoin, Eric Amela, Sandrine Ducornet, Jean-Pierre Meurant, Marie-Cécile Le Deley, Nicolas Penel
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background The primary aim of this trial was to determine the recommended phase II dose (RP2D) of weekly paclitaxel (wP) administered in combination with oral metronomic cyclophosphamide (OMC). Methods Patients ≥ 18 years of age with refra
Externí odkaz:
https://doaj.org/article/2d0c8fb4f093424a9c90a48b443e3956
Autor:
Stéphane Oudard, Alain Ravaud, Sylvie Negrier, Diego Tosi, Bernard Escudier, Eric Amela, Ellen Blanc, Christine Chevreau, Celine Ferlay, Frederic Rolland, Remy Delva
Publikováno v:
Clinical Genitourinary Cancer. 12:50-54
Background The expanded access program and anecdotal cases suggested sunitinib is safe in RCC patients with BM and might have worthwhile activity. Patients and Methods In a phase II trial, patients with untreated BM received the standard regimen of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4de093e1a08badc1fbae598f5810786
https://doi.org/10.1016/j.clgc.2013.09.008
https://doi.org/10.1016/j.clgc.2013.09.008
Autor:
Charlotte, Peugniez, Tarek, Ghoneim, Xavier, Leroy, Eric, Amela, Jean-Christophe, Fantoni, Stéphane, Culine, Arnauld, Villers, Antoine, Adenis
Publikováno v:
Bulletin du cancer. 100(5)
Urachal cancer is a rare pathology (less than 1% among all bladder tumors) with a poor prognosis for all stages, because of clinical delay leading to a late diagnosis, difficult differential diagnosis with bladder cancer, and no consensus for the tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7094950475d92c039a4ad330e9803078
https://pubmed.ncbi.nlm.nih.gov/23501769
https://pubmed.ncbi.nlm.nih.gov/23501769